Whether you are a new T1D Family, a TrialNet participant, a healthcare provider, or a researcher — you'll find resources here.
We’re here to help you after a new T1D diagnosis. Get answers to frequently asked questions and learn about clinical studies testing ways to maintain insulin production.
While you wait for screening results, get answers to your questions, find out about next steps, and learn more about TrialNet’s Pathway to Prevention.
Your T1D families are important to you. Learn how easy it is to connect your patients with world-class T1D research.
Riley Hospital for Children is one of twenty-five Type 1 Diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Principal Investigator, Linda DiMeglio, MD, the TrialNet team at the Riley's is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
University of Michigan Health System
1500 E. Medical Center Dr, Ann Arbor, MI 48109
Ann & Robert H. Lurie Childrens Hospital of Chicago
225 E Chicago, Chicago, IL 60611
St. Johns Hospital & Medical Center
22201 Moross Road, SCPB II, Suite 270, Detroit, MI 48236
Henry Ford Medical Center
3031 West Grand Blvd, Detroit, MI 48202
Childrens Hospital of Michigan
3901 Beaubien Blvd, Detroit, MI 48201
Lutheran Childrens Hospital
7950 W. Jefferson Blvd, suite 210, Fort Wayne, IN 46804
DeVos Childrens Hospital at Spectrum Health Hospitals
15 Michigan Street NE, Suite 701, Grand Rapids, MI 49503
Presence Saint Joseph Medical Center
333 N. Madison St., Joliet, IL 60435
Western Michigan University School of Medicine
1000 Oakland Drive, Kalamazoo, MI 49008
University of Kentucky
1101 Veterans Drive 111-C, Lexington, KY 40502
University of Illinois College of Medicine at Peoria
530 NE Glen Oak Ave, Peoria, IL 61637
1130 South 6th St. Ste. 100, Springfield, IL 62703
The University of Toledo
2142 North Cove Blvd., Conrad Jobst Tower, Suite 980, Toledo, OH 43606
If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.
TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.
We tested the drug teplizumab to see if it could delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D.
Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.